BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK

BioTime, Inc. (NYSE MKT: BTX) today announced that Co-Chief Executive Officer Michael D. West, Ph.D. will deliver a presentation at “Stem Cells in Drug Discovery 2016” on Wednesday, April 6 at 10:00 a.m. BST, in Cambridge, England.

Dr. West’s presentation is titled, “Novel Strategies for the Robust and Reproducible Production of Diverse Cell Types from Pluripotent Stem Cells for Drug Discovery.” Dr. West will describe the application of BioTime’s PureStem® technology for the robust and reproducible generation of diverse human cell types for drug discovery, and its benefits vis-a-vis animal models and alternative stem cell-based strategies. Dr. West’s presentation will be made available on BioTime’s website at www.biotimeinc.com.

The two-day event will bring together some of the preeminent scientists in the field, dedicated to exploring the basis of using human stem cells as an avenue to presenting a more accurate model for pre-clinical testing, as well as discussion about how stem cells are revolutionizing in vitro disease models, assay development, toxicology studies and lead generation in drug discovery.

More information on Stem Cells in Drug Discovery 2016 is available at Select Biosciences.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry, as the various programs and product lines have advanced through basic research and animal studies. We and our subsidiaries now have four therapeutic product candidates in human clinical trials, each of which addresses a large market opportunity. In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and stem cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160405005764/en/